Clinical Trial Update: Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents [Phase 3]

View source ↗

Summary

This clinical trial update reports Phase 3 results on secukinumab (AIN457) in active rheumatoid arthritis patients with inadequate response to anti-TNF therapy.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2017-03-29